Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Donne Bennett Caces"'
Autor:
Arnon Kater, Brandon Hodkinson, Carol Moreno, Talha Munir, Mark-David Levin, Carsten Niemann, Keqin Qi, Pierre Sinet, Kurt Baeten, Donne Bennett Caces, Srimathi Srinivasan
Publikováno v:
HemaSphere, Vol 7, p e56748d2 (2023)
Externí odkaz:
https://doaj.org/article/ab02621cd80c4e28ab027ee121604d82
Autor:
Talha Munir, Carol Moreno, Carolyn Owen, George Follows, Ohad Benjamini, Ann Janssens, Mark-David Levin, Anders Osterborg, Tadeusz Robak, Martin Simkovic, Don Stevens, Sergey Voloshin, Vladimir Vorobyev, Munci Yagci, Loic Ysebaert, Qianya Qi, Andrew Steele, Natasha Schuier, Kurt Baeten, Donne Bennett Caces, Carsten Niemann, Arnon Kater
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:S116
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::34aa7a49faadef3598cddf96c8377007
https://doi.org/10.1016/s2152-2650(22)00696-6
https://doi.org/10.1016/s2152-2650(22)00696-6
Autor:
Talha Munir, Carol Moreno, Carolyn Owen, George Follows, Ohad Benjamini, Ann Janssens, Mark-David Levin, Anders Osterborg, Tadeusz Robak, Martin Simkovic, Don Stevens, Sergey Voloshin, Vladimir Vorobyev, Munci Yagci, Loic Ysebaert, Qianya Qi, Andrew Steele, Natasha Schuier, Kurt Baeten, Donne Bennett Caces, Carsten Niemann, Arnon Kater
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:S138
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c550f978f47c190c7414c92a02d868d8
https://doi.org/10.1016/s2152-2650(22)00838-2
https://doi.org/10.1016/s2152-2650(22)00838-2
Autor:
Carsten Utoft Niemann, Vladimir I. Vorobyev, Ann Janssens, Andrew Steele, Ohad Benjamini, Tadeusz Robak, Don A. Stevens, Arnon P. Kater, Carolyn Owen, Loic Ysebaert, Donne Bennett Caces, George A Follows, Natasha Schuier, Tahla Munir, Mark-David Levin, Anders Österborg, Martin Simkovic, Munchi Yagci, Carol Moreno, Sergey Voloshin, Qianaya Qi, Kurt Baeten
Publikováno v:
Blood. 138:70-70
Background: MRD status is an established predictive marker for progression-free survival (PFS) in CLL following chemoimmunotherapy as well as for fixed-duration treatment with venetoclax and an anti-CD20 antibody. To date, this relationship has not b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b574f5092e0741ef191745d3c347ecac
https://doi.org/10.1182/blood-2021-148666
https://doi.org/10.1182/blood-2021-148666